The global Neurological Biomarkers market size is expected to reach USD 26.14 billion by 2030 and is expected to expand at a CAGR of 20.9% from 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38501
Growth Factors
Increasing funding for the R&D of neurological biomarkers to boost the development of new drugs is expected to accelerate market growth. Moreover, the introduction of novel innovative products for the diagnosis of neurological biomarkers is expected to propel market growth over the forecast period.
The National Institute of Neurological Disorders and Stroke provides funding, such as development grants & cooperative agreements for researchers conducting studies related to biomarker discovery, analytical validation, & clinical validation. Thus, the presence of organizations offering funds at various stages of research is anticipated to drive market growth.
Report Coverage
| Report Coverage | Details |
| Market Size | USD 26.14 billion by 2030 |
| Growth Rate | CAGR of 20.9% From 2021 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Type, Application, End-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Abbott; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; BANYAN BIOMARKERS, INC.; Myriad Genetics, Inc.; DiaGenic ASA; and Quanterix |
Report Highlights
The proteomic segment accounted for the highest revenue share of over 42% in 2020. Genomic biomarkers accounted for the second-largest market share in 2020. Genomic biomarkers present promising opportunities for the development of personalized medicines and diagnostics based on an individual’s specific genetic variations & predisposition to the disease. The others segment is anticipated to witness significant CAGR over the forecast period due to the increasing adoption of digital biomarkers in clinical trials patient selection for neurological drugs.
The Alzheimer’s disease application segment accounted for the largest market share of over 44% in 2020 and is expected to remain dominant during the forecast period. This growth is credited to the high disease burden and availability of products for clinical use, such as imaging biomarkers-amyloid PET tracers for diagnosis. Furthermore, the government and non-profit organizations are providing a plethora of research opportunities that may fuel market growth.
The Parkinson’s disease application segment is expected to grow at a CAGR of 23.2% during the forecast period owing to the growing prevalence of the disease and an increasing number of clinical trials for the disease drugs. The hospital & hospital laboratories segment accounted for the largest market share of over 38% in 2020. The segment is expected to remain dominant even during the forecast period due to a rise in hospitalization. Furthermore, the ongoing development of healthcare infrastructure is anticipated to enhance the existing hospital facilities. Most of the blood-based biomarker assays are purchased by hospitals and are used in significant volumes.
North America accounted for the highest market share of over 51.07% in 2020 and is expected to witness a significant growth rate over the forecast period. The significantly high disease burden, acceptance of biomarkers for diagnostic, drug development & prognostic purposes, and increase in research funding are some key factors contributing to the dominance of the region.
Key Players
- Abbott Laboratories
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Banyan Biomarkers, Inc.
- Myriad Genetics, Inc.
- DiaGenic ASA
- Quanterix
Market Segmentation
- Type
- Genomic
- Proteomic
- Metabolomic
- Imaging
- Others
- Application
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Autism Spectrum Disorder
- Others
- End-use
- Hospital & Hospital Laboratories
- Independent Clinical Diagnostic Centers
- Research Organizations and Others
- Regional
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia Pacific
- India
- China
- Japan
- Australia
- South Korea
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- North America
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38501
Reasons to Purchase this Report:
– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Neurological Biomarkers Market, By Type
7.1. Neurological Biomarkers Market, by Type, 2021-2030
7.1.1. Genomic
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Proteomic
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Metabolomic
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Imaging
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Others
7.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Neurological Biomarkers Market, By Application
8.1. Neurological Biomarkers Market, by Application, 2021-2030
8.1.1. Alzheimer’s Disease
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Parkinson’s Disease
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Multiple Sclerosis
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Autism Spectrum Disorder
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Neurological Biomarkers Market, By End User
9.1. Neurological Biomarkers Market, by End User, 2021-2030
9.1.1. Hospital & Hospital Laboratories
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Independent Clinical Diagnostic Centers
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Research Organizations and Others
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Neurological Biomarkers Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.1.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Type (2017-2030)
10.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.2.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Type (2017-2030)
10.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.3.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.6.3. Market Revenue and Forecast, by End User (2017-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Type (2017-2030)
10.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
10.4.7.3. Market Revenue and Forecast, by End User (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.4.3. Market Revenue and Forecast, by End User (2017-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Type (2017-2030)
10.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
10.5.5.3. Market Revenue and Forecast, by End User (2017-2030)
Chapter 11. Company Profiles
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Thermo Fisher Scientific, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Bio-Rad Laboratories, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Merck & Co., Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Johnson & Johnson Services, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Banyan Biomarkers, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Myriad Genetics, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. DiaGenic ASA
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Quanterix
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38501
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
